Brought to you by 
NanoString's Series D round brings in $20mm
17 Nov 2011
Executive Summary
Molecular diagnostics company NanoString Technologies Inc. raised $20mm through its Series D round. New investors GE Healthymagination Fund (managed by GE Healthcare and GE Capital), BioMed Ventures, and former Genzyme CEO Henri Termeer were joined by returning backers Clarus Ventures, Draper Fisher Jurvetson, and OVP Venture Partners. Some of the proceeds will be used to advance development of NanoString's first molecular test, a PAM50 gene expression assay for breast cancer.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NanoString's Series D round brings in $20mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice